Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: Data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia.
Dmitry LioznovIrina AmosovaSavely A SheetikovKsenia V ZornikovaYana SerdyukGrigory A EfimovMikhail TsyferovMikhail KhmelevskiiAndrei AfanasievNadezhda F KhomyakovaDmitry ZubkovAnton TikhonovTao ZhuLuis BarretoVitalina DzutsevaPublished in: PloS one (2023)
Trial registration: ClinicalTrials.gov: NCT04540419.